1) Strong Financial Performance - Q2 revenue increased by 10% YoY to $11.99 billion. - Adjusted operating income rose 15% to $2.73 billion, with an adjusted operating margin of 22.8%, up 90 basis points. - Adjusted EPS grew 13% to $6.03 per share. - Organic revenue growth was 5%, with a $300 million revenue beat compared to previous guidance.

2) Segment Highlights and Growth Strategy - Pharma and Biotech: Mid-single-digit growth, driven by Bioproduction and Clinical Research. - Academic and Government: Low single-digit growth, primarily from Chromatography and Mass Spectrometry. - Industrial and Applied: Mid-single-digit growth, led by Electron Microscopy and Chemical Analysis. - Diagnostics and Health Care: Mid-single-digit growth, driven by Health Care market channel and Immunodiagnostics. - Continued focus on high-impact innovation, including new mass spectrometry platforms and AI-driven capabilities, enhancing customer engagement and operational efficiency.

3) Capital Deployment and Acquisitions - Successful integration of Clario, enhancing clinical insights for pharma and biotech customers. - Announced divestiture of microbiology business expected to close in Q3, with proceeds used for $1 billion share repurchase in Q2. - Active M&A pipeline in a fragmented industry, with disciplined capital deployment strategy focusing on strategic acquisitions and shareholder returns.

4) Guidance and Outlook - Full-year revenue guidance raised to $47.4 billion - $48.1 billion, reflecting 6% to 8% growth over 2025. - Adjusted EPS guidance increased to $24.93 - $25.33, representing 9% to 11% growth. - Organic revenue growth expectation increased to about 4% for the year, with Q3 and Q4 anticipated to show similar growth rates.

5) Market Dynamics and Challenges - Continued positive trends in pharma and biotech spending, with signs of stabilization in academic and government markets. - Challenges remain in the macroeconomic environment, particularly in China, which grew low single digits but is showing signs of recovery. - The impact of the microbiology divestiture and foreign exchange fluctuations noted, with expected dilutive effects on EPS.

Bottom line: Thermo Fisher Scientific delivered a robust Q2 with strong revenue and EPS growth, driven by solid performance across all segments and effective capital deployment strategies. The company is well-positioned for continued growth, raising its full-year guidance amid improving market conditions, particularly in pharma and biotech.